Buy Gastrosol capsules 20 mg, 14 pcs
  • Buy Gastrosol capsules 20 mg, 14 pcs

Omeprazole

Pharmstandard
1401 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$18.25
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Gastrozole is anti-ulcer.

Inhibits H+K+ATPase (proton pump) in the parietal cells of the stomach and blocks the final stage of basal and stimulated secretion of hydrochloric acid.

Pharmacodynamics

It easily penetrates the cells of the gastric mucosa and has a cytoprotective effect. Reception at a dose of 20 mg maintains a pH value of up to 3 for 16 hours, lasts for 24 hours. It has an anti-helicobacter effect: it shows a bactericidal effect due to the accumulation of ammonium in the antrum of the stomach and increases the number of vegetative forms that are mainly affected by antibiotics in the fundic department .

Pharmacokinetics

Quickly and completely absorbed from the gastrointestinal tract (food intake does not affect the speed). Cmaxafter a single dose, 40 mg is achieved in 2–3 hours. In the blood, 95% binds to plasma proteins. Almost completely biotransformed in the liver and excreted in the urine as metabolites. T1/2 - 0.5–3 h.

Indications

Peptic ulcer and duodenal ulcer, incl. peptic ulcer associated with H. pylori, reflux esophagitis, Zollinger-Ellison syndrome, erosive and ulcerative lesions of the gastrointestinal tract caused by NSAIDs; acid suction prevention.

Composition

1 capsule contains:

Active substance: omeprazole 20 mg;

Excipients: mannitol, sucrose, sodium lauryl sulfate, sodium hydrogen phosphate (disodium phosphate disubstituted), calcium carbonate, lactose, hypromellose (hydroxypropylmethylcellulose), methacrylic acid and ethyl acrylate copolymer (methacrylic acid copolymer L30D), propylene glycol, and ethyl acetate, polyethyl acrylate (methacrylate acid copolymer L30D), propylene glycol, and ethyl acetate, polyethyl acetate, polyethyl acrylate (L30D methylacrylate acid copolymer, hydroxypropylmethyl cellulose), methylacrylate (tween-80), povidone (polyvinylpyrrolidone), titanium dioxide, talc;

The composition of the body and caps of the capsules: ferric oxide red (E172), titanium dioxide (E171), methyl parahydroxybenzoate (methylhydroxybenzoate), propyl parahydroxybenzoate (propyl hydroxybenzoate), gelatin; or iron oxide red (E172), titanium dioxide (E171), gelatin.

Omeprazole is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Gastrosol Pharmstandard Russia capsules
Omez Dr. Reddy`s India capsules
Omeprazole-OBL Obolensky OP Russia capsules
Omeprazole-Teva Teva Israel capsules
Ortanol® Sandoz Switzerland capsules
Omez Dr. Reddy`s India powder
Omez Dr. Reddy`s India lyophilisate
Ultop Krka dd Novo mesto AO Slovenia bottle
Ultop Krka dd Novo mesto AO Slovenia capsules
Omitox Shreya India capsules
Losec MUPS® AstraZeneca UK pills

No customer reviews for the moment.

Write your review

Write your review

Omeprazole

Dosage and Administration

Orally, in the morning, on an empty stomach, without chewing and washing down with a small amount of liquid.

With the exacerbation of gastric ulcer and duodenal ulcer - 20 mg 1 time per day, if necessary, the dose can be increased to 40 mg 1 time per day. The duration of treatment varies from 4 (in patients with duodenal ulcer) to 8 weeks (in patients with gastric ulcer). In case of poor ulcer healing, it is recommended to prescribe the drug for another 4 weeks.

Forprevention of recurrence of gastric ulcer and duodenal ulcer - 20–40 mg (if necessary) 1 time per day.

Withreflux esophagitis - 20–40 mg once daily for 4–12 weeks.

WithZollinger-Ellison syndrome - the dose is set individually. The recommended initial dose is 60 mg once a day. A dose exceeding 80 mg / day should be divided into 2 doses (every 12 hours), a dose exceeding 120 mg should be divided into 3 doses.

Foracid suction prevention - 40 mg in the evening before surgery and 40 mg in 1-4 hours before the procedure.

Treatment of erosive and ulcerative lesions caused by taking NSAIDs - 20 mg 1 time per day for 4 weeks, if necessary, treatment can be continued for another 4 weeks. For the prevention of relapse, maintenance therapy at a dose of 20 mg is recommended.

Withpeptic ulcer associated with Helicobacter pylori There are several schemes of combination therapy ("triple" or "double"):

  • 20 mg Gastrozole, 1 g of amoxicillin and 500 mg of clarithromycin 2 times a day for 1 week;
  • 20 mg Gastrozole, 250 mg clarithromycin and 400 mg metronidazole 2 times a day for 1 week;
  • 40 mg Gastrozole, 500 mg of amoxicillin and 400 mg of metronidazole 3 times a day for 1 week;
  • 20–40 mg Gastrozole 1 time per day, 500 mg clarithromycin 3 times a day and 0.75–1 g amoxicillin 2 times a day for 2 weeks;
  • 40 mg Gastrozole and 750 mg Amoxicillin 2 times a day for 2 weeks.

Patients with impaired liver function, the maximum daily dose is 20 mg.

Adverse reactions

From the nervous system and sense organs: dizziness, headache, agitation, depression.

Since the cardiovascular system and blood (hematopoiesis, hemostasis): leuco-, thrombocytopenia, agranulocytosis.

On the part of the digestive tract: dry mouth, nausea, vomiting, abdominal pain, flatulence, diarrhea or constipation, increased activity of hepatic transaminases.

From the musculoskeletal system: arthralgia, myalgia.

On the part of the skin: photosensitization, alopecia, erythema multiforme.

Allergic reactions: urticaria, skin rash.

Contraindications

Hypersensitivity.

Drug interactions

Strozol may reduce the absorption of ampicillin esters, iron salts, itraconazole and ketoconazole, since Omeprazole increases the pH of the stomach.

As an inhibitor of isoenzymes of the cytochrome P450 system, omeprazole can increase plasma concentrations and reduce the excretion of diazepam, indirect anticoagulants, phenytoin (drugs metabolized in the liver with the participation of CYP2C19), which in some cases may require a reduction in doses of these drugs.

With long-term use of omeprazole in a dose of 20 mg 1 time / day. in combination with caffeine, theophylline, piroxicam, diclofenac, naproxen, metoprolol, propranol, ethanol, cyclosporine, quinidine and estradiol did not lead to a change in their concentration in plasma.

Gastrozole enhances the inhibitory effect on the hematopoietic system of other drugs.

No interaction of omeprazole with concomitant antacids was observed.

Pregnancy and Lactation

The drug is contraindicated for use during pregnancy and lactation (breastfeeding).

Special instructions

Before starting treatment, it is necessary to exclude the presence of a malignant process (especially in case of gastric ulcer), since Gastrozole can mask the symptoms and delay the correct diagnosis.

Taking the drug at the same time with food does not affect its effectiveness.
Application for violations of the liver

Precautions should be used in patients with hepatic insufficiency.

Application for violations of renal function

Precautions should be used in patients with renal insufficiency.

Overdosage

Symptoms: confusion, blurred vision, drowsiness, dry mouth, headache, nausea, tachycardia, arrhythmia.

Treatment: conducting symptomatic therapy. Hemodialysis is not effective enough.

  • Brand name: Gastrosol
  • Active ingredient: Omeprazole
  • Dosage form: Capsules
  • Manufacturer: Pharmstandard
  • Country of Origin: Russia

Studies and clinical trials of Omeprazole (Click to expand)

  1. Effect of omeprazole in chronic idiopathic thrombocytopenic purpura
  2. Neuromyopathy secondary to Omeprazole treatment
  3. THE EFFECT OF CHANGES IN GASTRIC pH INDUCED BY OMEPRAZOLE ON THE ABSORPTION AND RESPIRATORY DEPRESSION OF METHADONE
  4. Omeprazole and visual disorders: seeing alternatives
  5. Gastric adenocarcinoma in a patient under immunosuppressive and omeprazole treatment
  6. Ocular disorders in users of H2 antagonists and of omeprazole
  7. Omeprazole-induced hepatotoxicity? A case report
  8. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers
  9. Variable omeprazole kinetics in healthy Jordanian adults
  10. Effects of omeprazole or cola beverage on the pharmacokinetics of oral DA-8159, a new erectogenic, in rats
  11. Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous omeprazole in rats
  12. Pharmacokinetics of omeprazole in rats with water deprivation for 72 hours
  13. Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects
  14. Faster clearance of omeprazole in mutant Nagase analbuminemic rats: possible roles of increased protein expression of hepatic CYP1A2 and lower plasma protein binding
  15. Liver regeneration is enhanced by omeprazole in rats following partial hepatectomy
  16. Laparoscopic Nissen fundoplication is a satisfactory alternative to long-term omeprazole therapy
  17. Randomized controlled trial of standard versus high-dose intravenous omeprazole after endoscopic therapy in high-risk patients with acute peptic ulcer bleeding
  18. Highly sensitive method for the determination of omeprazole in human plasma by liquid chromatography–electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study
  19. Simultaneous estimation of four proton pump inhibitors—lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study
  20. Influence of number of calibration standards within a defined range on pharmacokinetic disposition—case studies with omeprazole and clopidogrel carboxylic acid
  21. Enantioseparation of rabeprazole and omeprazole by nonaqueous capillary electrophoresis with an ephedrine-based ionic liquid as the chiral selector
  22. Effect of omeprazole on secretion, synthesis and the gene expression of pepsinogen in the guinea pig stomach mucosa
  23. Omeprazole and analogue compounds: a QSAR study of activity against Helicobacter pylori using theoretical descriptors
  24. ChemInform Abstract: Synthesis of 2-Hydroxymethyl-3,5-dimethyl-4-methoxypyridine: A Key Intermediate for Omeprazole.

Customers who bought this product also bought:

8 other products in the same category:

arrow_upward